Medicare Enrolled
Dr. Muhammad Imtiaz, M.D.
Pulmonary Disease · Johnstown, PA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Imtiaz from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Imtiaz?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Imtiaz
Dr. Muhammad Imtiaz is a pulmonary disease specialist in Johnstown, PA, with 17 years of NPI registration. Based on federal Medicare data, Dr. Imtiaz performed 1,032 Medicare services across 681 unique beneficiaries.
Between the years covered by Open Payments, Dr. Imtiaz received a total of $11,666 from 40 pharmaceutical and/or device companies across 525 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Imtiaz is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 28% volume in PA
$11,666 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,032
Medicare services
Top 28% in PA for pulmonary disease
681
Unique beneficiaries
$104
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~61 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
302 | $158 | $406 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
170 | $88 | $143 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
138 | $84 | $140 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
58 | $128 | $258 |
| Insertion of non-tunneled central venous catheter A procedure to place a central venous catheter for infusion in patients aged 5 years or older. The catheter is inserted directly into a large vein without being tunneled under the skin. |
42 | $64 | $346 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
39 | $105 | $203 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
35 | $124 | $195 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
28 | $26 | $128 |
| Arterial line insertion A tube is inserted into an artery through the skin to allow for blood sampling or infusion. |
26 | $34 | $148 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
26 | $37 | $110 |
| Lung volume test using gas dilution or washout A test that measures the amount of air in your lungs by using a gas dilution or washout method. |
25 | $29 | $98 |
| Bronchial irrigation and suction for cell collection This procedure uses an endoscope to flush and suction the lung airways in order to collect cells for testing. |
24 | $45 | $182 |
| New patient office visit, complex (60-74 min) | 19 | $162 | $253 |
| Endoscopic needle biopsy of windpipe, airway, or lung A procedure where a needle is inserted through an endoscope to collect tissue samples from the windpipe, airway, or lung. |
17 | $71 | $249 |
| Bronchoscopy with ultrasound and lymph node sampling A procedure using a scope and ultrasound to examine the airways and collect tissue samples from three or more lymph nodes. |
17 | $176 | $280 |
| Sedation by physician, initial 15 minutes Administration of a drug to induce depression of consciousness by the physician performing a procedure. This code covers the initial 15 minutes of sedation for patients aged 5 years or older. |
16 | $9 | $50 |
| Emergent tracheostomy An emergency procedure to create an opening in the windpipe to insert a breathing tube, guided by an endoscope. |
15 | $107 | $305 |
| Exercise-induced lung stress test A test performed to evaluate how the lungs function during physical exertion. It helps identify breathing difficulties or lung conditions that occur specifically when exercising. |
12 | $25 | $105 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
12 | $61 | $110 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
11 | $20 | $79 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
4.1% high complexity
4.5% medium
91.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$11,666
Total received (2018-2024)
Avg $1,667/year across 7 years
Top 16% in PA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
40
Companies
525
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$11,633 (99.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$32 (0.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,633
2023
$3,189
2022
$3,003
2021
$1,399
2020
$639
2019
$776
2018
$26
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
INTUITIVE SURGICAL, INC.
$591
GlaxoSmithKline, LLC.
$523
AstraZeneca Pharmaceuticals LP
$241
Boehringer Ingelheim Pharmaceuticals, Inc.
$234
Mallinckrodt Hospital Products Inc.
$216
Electromed, Inc.
$154
FUJIFILM Healthcare Americas Corporation
$145
GENZYME CORPORATION
$143
Amgen Inc.
$88
Philips North America LLC
$57
Actelion Pharmaceuticals US, Inc.
$56
Grifols USA, LLC
$40
PFIZER INC.
$30
Regeneron Healthcare Solutions, Inc.
$27
Shionogi Inc
$23
ABBVIE INC.
$19
Vifor Pharma, Inc.
$16
Pulmonx Corporation
$15
Insmed, Inc.
$15
Top 3 companies account for 51.5% of 2024 payments
All-time payments by company (2018-2024) ›
GlaxoSmithKline, LLC.
$2,717
AstraZeneca Pharmaceuticals LP
$1,476
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,006
GENZYME CORPORATION
$673
Intuitive Surgical, Inc.
$642
Electromed, Inc.
$621
INTUITIVE SURGICAL, INC.
$591
Pulmonx Corporation
$425
Grifols USA, LLC
$405
Regeneron Healthcare Solutions, Inc.
$390
Mallinckrodt Hospital Products Inc.
$388
Actelion Pharmaceuticals US, Inc.
$350
Amgen Inc.
$242
FUJIFILM Healthcare Americas Corporation
$145
ABBVIE INC.
$135
Philips Electronics North America Corporation
$118
E.R. Squibb & Sons, L.L.C.
$115
Insmed, Inc.
$112
Foundation Medicine, Inc.
$112
Teva Pharmaceuticals USA, Inc.
$109
PFIZER INC.
$94
Mylan Specialty L.P.
$78
Penumbra, Inc.
$78
Janssen Pharmaceuticals, Inc
$77
Takeda Pharmaceuticals U.S.A., Inc.
$75
Genentech USA, Inc.
$63
Philips North America LLC
$57
Novartis Pharmaceuticals Corporation
$53
Baxter Healthcare
$47
JAZZ PHARMACEUTICALS INC.
$47
Advanced Respiratory, Inc
$35
Paratek Pharmaceuticals, Inc.
$32
Ethicon Inc.
$31
Shionogi Inc
$23
Resmed Corp
$22
United Therapeutics Corporation
$20
Vifor Pharma, Inc.
$16
Covis Pharma GmBH
$15
Merck Sharp & Dohme Corporation
$15
PORTOLA PHARMACEUTICALS, LLC
$15
Top 3 companies account for 44.6% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · ACTHAR · AIRSUPRA · ALVESCO · ANDEXXA · ANORO ELLIPTA · AREXVY · AVYCAZ · AirDuo Digihaler · Arikayce · Astral · BREO · BREZTRI · BREZTRI AEROSPHERE · CHARTIS CATHETER · CUTAQUIG · DUPIXENT · Da Vinci Surgical System · ELIQUIS · FASENRA · FOUNDATIONONE · FUJIFILM · Fetroja · GLASSIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · Indigo System · Monarch Platform · NUCALA · NUZYRA · OFEV · OPDIVO · OPSUMIT · PREVNAR 20 · Prolastin-C Liquid · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · TABRECTA · TEFLARO · TERLIVAZ · TEZSPIRE · TRELEGY ELLIPTA · TYVASO · The Vest System Model 105 Home Care · UPTRAVI · Veltassa · XARELTO · XOLAIR · XYREM · Xolair · YUPELRI · Yupelri
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
6
Per 100K population
4.5
County median income
$56,292
Nearest hospital
CONEMAUGH MEMORIAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Imtiaz is a clinical cardiology specialist, with above-average Medicare volume (top 28% in PA), with low-engagement industry engagement in the top 16% of PA peers, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Imtiaz experienced with critical care, first 30-74 min?
Based on Medicare claims data, Dr. Imtiaz performed 302 critical care, first 30-74 min services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Imtiaz receive payments from pharmaceutical companies?
Yes. Dr. Imtiaz received a total of $11,666 from 40 companies across 525 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Imtiaz's costs compare to other pulmonary diseases in Johnstown?
Dr. Imtiaz's average Medicare payment per service is $104. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Imtiaz) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Johnstown
Browse pulmonary diseases in Johnstown ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in PA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in PA
Which PA pulmonary diseases receive the most from drug and device companies.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology